When was retatrutide first described?

Coskun and colleagues published its discovery in Cell Metabolism in September 2022.

Has it been approved anywhere?

No. It remains investigational in every jurisdiction, with an FDA filing signalled for Q1 2027.

What is still outstanding?

Maintenance-dosing data. TRIUMPH-6 has a primary completion date of April 2028.

The History of Retatrutide

The short answer

Retatrutide was described by Coskun and colleagues in Cell Metabolism in September 2022. Phase 2 results appeared in the New England Journal of Medicine in 2023, and the Phase 3 TRIUMPH programme reported from December 2025 through July 2026, with an FDA filing signalled for Q1 2027.

Key facts

Discovery paper: Coskun, Cell Metab, Sept 2022
Phase 2: Jastreboff, NEJM 2023 (PMID 37366315)
Phase 2 in T2D: Rosenstock, Lancet 2023 (PMID 37385280)
First Phase 3 readout: TRIUMPH-4, December 2025
Pivotal readout: TRIUMPH-1, 21 May 2026
Signalled FDA filing: Q1 2027
Approvals: None, anywhere

The discovery paper

Coskun and colleagues published LY3437943's discovery and characterisation in Cell Metabolism in September 2022, subtitled from discovery to clinical proof of concept. It describes the design objective (balanced agonism across GIP, GLP-1 and glucagon receptors) and the pharmacology achieved. It remains the primary structural reference.

Phase 2 and the numbers that drew attention

Jastreboff and colleagues reported the Phase 2 obesity trial in the New England Journal of Medicine in 2023, and Rosenstock and colleagues reported in adults with type 2 diabetes in the Lancet the same year. The obesity figures were the largest then reported for any single-molecule incretin agonist, which is what made retatrutide the compound the field watched.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £49.99

The Phase 3 programme

TRIUMPH enrolled more than 5,800 participants. TRIUMPH-4 reported first in December 2025. TRIUMPH-1, the pivotal obesity study, reported on 21 May 2026. TRIUMPH-2 and TRIUMPH-3 followed in July 2026, covering type 2 diabetes and established cardiovascular disease. All met their primary endpoints.

Where it stands now

Investigational everywhere. Lilly has signalled a Biologics License Application to the FDA in the first quarter of 2027, and no MHRA or EMA timeline has been announced. Further readouts including maintenance-dosing studies remain outstanding; TRIUMPH-6 has a primary completion date of April 2028.

A citation worth getting right

The two Phase 2 papers are frequently miscited. Jastreboff's NEJM paper is PMID 37366315 and Rosenstock's Lancet paper is PMID 37385280. This library previously carried neighbouring PMIDs that resolved to a paediatric ophthalmology paper and a cardiothoracic surgery commentary. They were corrected earlier this week, and are a reasonable illustration of how easily a plausible-looking identifier goes wrong.

Frequently asked questions

When was retatrutide first described?: Coskun and colleagues published its discovery in Cell Metabolism in September 2022.
Has it been approved anywhere?: No. It remains investigational in every jurisdiction, with an FDA filing signalled for Q1 2027.
What is still outstanding?: Maintenance-dosing data. TRIUMPH-6 has a primary completion date of April 2028.

Extended research context

The Retatrutide Research deep dive

Deep dive: how the triple-agonist scaffold was engineered

Retatrutide's 39-residue backbone was designed by Eli Lilly's peptide chemistry team to preserve the pharmacophores of three glucagon-family receptors on a single chain. The N-terminal domain retains GIP-receptor contacts, mid-chain substitutions restore GLP-1-receptor affinity lost in native GIP, and additional residue swaps confer glucagon-receptor engagement. A γGlu-2xOEG linker anchors a C20 fatty diacid at Lys17, which reversibly binds serum albumin and slows renal clearance. This is the same albumin-tethering strategy Novo Nordisk pioneered with semaglutide and Lilly refined further in tirzepatide.

The TRIUMPH Phase 3 programme in context

TRIUMPH is Lilly's global Phase 3 development umbrella for retatrutide, spanning obesity (TRIUMPH-1 through TRIUMPH-4), type 2 diabetes, MASH (metabolic dysfunction-associated steatohepatitis), and knee osteoarthritis linked to obesity. Readouts began in 2025 and continue through 2026. Because the compound is investigational, no regulator (FDA, EMA, or MHRA) has issued marketing authorisation, and legitimate supply exists only for laboratory reference and research contexts, never for human administration.

How retatrutide differs from tirzepatide and semaglutide at the mechanism level

Semaglutide is a mono-agonist (GLP-1 only). Tirzepatide is a dual agonist (GIP + GLP-1). Retatrutide adds glucagon-receptor activity, which pre-clinical and Phase 2 data suggest contributes to energy expenditure in addition to appetite regulation and glucose-dependent insulin release. This three-receptor combination is why retatrutide is sometimes called a 'metabolic multi-tool' peptide in the trade press, but the pharmacology is more nuanced than the label implies.

Research applications

▸In vitro receptor-binding assays across GIP-R, GLP-1R and GCGR panels
▸Comparator studies alongside semaglutide, tirzepatide and liraglutide reference standards
▸Analytical-method development: HPLC retention profiling and LC-MS confirmation
▸Stability testing of lipidated 39-residue peptides in aqueous and lyophilised forms
▸Reference material for teaching incretin pharmacology in university-level courses

Handling checklist

✓Store lyophilised vials at −20 °C; protect from light and humidity
✓Reconstitute with bacteriostatic water; avoid vortexing (foams the peptide)
✓Once reconstituted, store at 2–8 °C and use within 28 days
✓Verify batch CoA: HPLC ≥98%, mass matches ~4,731 Da, endotoxin low
✓Do not administer to humans or animals. Research use only

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Confusing retatrutide with tirzepatide in supplier catalogues

Fix: Cross-check the LY code (LY3437943 = retatrutide; LY3298176 = tirzepatide) and the receptor profile on the CoA.

✗ Using tap or filtered water for reconstitution

Fix: Only use bacteriostatic water for injection (0.9% benzyl alcohol) or sterile water, never lab DI water.

✗ Storing reconstituted solution at room temperature

Fix: Refrigerate at 2–8 °C immediately after reconstitution; discard after 28 days.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

UKP

Written and reviewed by

The UK Peptides Editorial Team · Research library, UK Peptides

The editorial team is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate. Corrections are made in place and the review date updated.

How we write and check this content Report a factual error in this article

Popular across the research hub

One flagship guide from every other research category.

← Back to Forum